CROI 2015 Program and Abstracts

Oral Sessions

62 Longitudinal Assessment of Blood Brain Barrier Disruption in Primary HIV Infection Elham Rahimy 1 ; Fang-yong Li 2 ; Alex Russell 4 ; Julia Peterson 4 ; Lars Hagberg 3 ; Henrik Zetterberg 3 ; Richard Price 4 ; Magnus Gisslén 3 ; Serena Spudich 1 1 Yale University School of Medicine, New Haven, CT, US; 2 Yale Center for Analytical Sciences, Yale University, New Haven, CT, US; 3 University of Gothenburg, Gothenburg, Sweden; 4 University of California San Francisco, San Francisco, CA, US 63 Declining Prevalence of HIV-Associated Neurocognitive Disorders in More Recent Years Carmela Pinnetti ; Raffaella Libertone; Pietro Balestra; Patrizia Lorenzini; Martina Ricottini; Samanta Menichetti; Maria Maddalena Plazzi; Mauro Zaccarelli; Adriana Ammassari; Andrea Antinori National Institute for Infectious Diseases, Lazzaro Spallanzani, Rome, Italy potential therapeutic and prophylactic applications of anti-HIV antibodies. Level of knowledge: It is assumed that participants are familiar with basic immunologic principles, antibody structure, and HIV envelope variability. Objectives: At the completion of the session, participants will be able to: • List cutting-edge approaches for the delivery of protective and curative antibodies. • Describe emerging approaches to enhance monoclonal antibody activity against virus. • Describe new advances in the ability to elicit antibodies that resemble neutralizing antibodies through vaccination. Symposium Conveners Leonidas Stamatatos , Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US Susan Zolla-Pazner , New York University, Langone Medical Center 64 Potentiating Protective Antibody Activity: A Systems Serology Approach Margaret E. Ackerman Thayer School of Engineering, Dartmouth College, Hanover, NH, US 65 Impact of Repetitive Protein Boosting on RV305 HIV-1 Vaccine-Induced Antibodies Georgia D. Tomaras Duke University Medical Center, Durham, NC, US 66 Immunoprophylaxis by Gene Transfer: Shortcut to an HIV Vaccine Phil Johnson Children’s Hospital of Philadelphia, Philiadlphia, PA, US 67 Broadly Neutralizing Antibodies for HIV-1 Eradication Strategies Dan H. Barouch Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US Session S-2 Symposium Room 6D 4:00 pm– 6:00 pm Current Issues in HIV-Related Malignancies Target audience: This session is directed to those interested in development and management of cancers in HIV. Level of knowledge: It is assumed that participants have some basic knowledge of types of cancers seen in HIV. Session S-1 Symposium Room 6C 4:00 pm– 6:00 pm Harnessing Antibodies for Prevention and Therapeutics Target audience: This session is directed to scientists and clinicians interested in the

Objectives: At the completion of the session, participants will be able to: • Discuss differences in malignancy incidence and presentation, including in resource-limited settings around the world. • Describe new concepts in viral-induced oncogenesis. • Describe new therapies for lymphoma in HIV-infected individuals. • Examine major barriers for treatment of cancers in resource-limited settings. Symposium Conveners Margaret Z. Borok , University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe Robert Yarchoan , National Cancer Institute, Bethesda, MD, US 68 HIV-Associated Malignancies: TheWorldwide Epidemic James J. Goedert National Cancer Institute, Bethesda, MD, US 69 Viral Oncogenesis: Evolving Concepts Shannon C. Kenney University of Wisconsin, Madison, WI, US 70 AIDS Lymphoma: Advances and Existing Challenges Ariela Noy Memorial Sloan Kettering Cancer Center, New York, NY, US 71 HIV Malignancies in Low- and Middle-Income Countries: A Double Burden of Disease Jackson Orem Uganda Cancer Institute, Kampala, Uganda Session S-3 Symposium Room 6AB 4:00 pm– 6:00 pm Current Imperatives in HIV Prevention and Treatment Target audience: This session is directed to researchers, public health professionals, and educators interested in global HIV and public health. Level of knowledge: It is assumed that participants are familiar with HIV program scale-up and global disease burden. Objectives: At the completion of the session, participants will be able to: • Define trends in HIV/AIDS and sexually transmitted infection epidemiology among different groups. • Describe the epidemiology of HIV among men who have sex with men in Africa, and associated challenges. • Assess broader impact on health programs and behavioral science of HIV/AIDS service scale-up. Symposium Conveners Wafaa M. El-Sadr , ICAP at Columbia University, New York, NY, US Lucy Ng’ang’a , CDC Center for Global Health, Division of Global AIDS/ HIV, Nairobi, Kenya 72 How Has HIV Prevention Affected the Spread of Other Sexually Transmitted Infections? Marie Laga Institute of Tropical Medicine, Antwerp, Belgium 73 HIV Risks and Vulnerabilities Among Gay Men and Other Men Who Have Sex With Men Across Sub-Saharan Africa Stefan Baral Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US 74 An Expanded Behavioral Paradigm for Treatment and Prevention of HIV-1 Thomas J. Coates University of California Los Angeles, Los Angeles, CA, US 75 Social Protection, Financial Incentives, and Prevention of HIV DavidWilson World Bank, Washington, DC, US

Tuesday, February 24, 2015 • Oral Sessions

8

CROI 2015